[1] KOWALSKI A,KRIKORIAN A,LERMA E V,Diabetes and chronic kidney disease[J].Dis Mon,2015,61(9):378-386.
[2] SANCHEZ A P,SHARMA K,Transcription factors in the pathogenesis of diabetic nephropathy[J].Expert Rev Mol Med,2009,11:e13.
[3] SCHRIJVERS B F,de VRIESE A S,FLYVBJERG A.From hyperglycemia to diabetic kidney disease:the role of metabolic,hemodynamic,intracellular factors and growth factors/cytokines[J].Endocr Rev,2004,25(6):971-1010.
[4] JAIKUMKAO K,PONGCHAIDECHA A,CHATSUDTHIPONGB V,et al.The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes[J].Biomedicine & Pharmacotherapy,2017,94:176-187.
[5] DURAN-SALGADO M B,RUBIO-GUERRA A F.Diabetic nephropathy and inflammation[J].World J Diabetes,2014,5(3):393-398.
[6] SATIRAPOJ B,ADLER S G.Comprehensive approach to diabetic nephropathy[J].Kidney Res Clin Pract,2014,33(3):121-131.
[7] HEDIGER M A,RHOADS D B.Molecular physiology of sodium-glucose cotransporters[J].Physiol Rev,1994,74(4):993-1026.
[8] RAHMOUNE H,THOMPSON P W,WARD J M,et al.Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes[J].Diabetes,2005,54(12):3427-3434.
[9] FARBER S J,BERGER E Y,EARLE D P.Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose[J].J Clin.Invest,1951,30(2):125-129.
[10] KATSUNO K,FUJIMORI Y,TAKEMURA Y,et al.Sergliflozin a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2),validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level[J].J Pharmacol Exp Ther,2007,320(1):323-330.
[11] GRONBAEK H,VOGEL I,OSTERBY R,et al.Effect of octreotide,captopril or insulin on renal changes and UAE in long-term experimental diabetes[J].Kidney Int,1998,53(1):173-180.
[12] MAGEE G M,BILOUS R W,CARDWELL C R,et al.Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis[J].Diabetologia,2009,52(4):691-697.
[13] ARAKAWA K,ISHIHARA T,OKU A,et al.Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095[J].Br J Pharmacol,2001,132(2):578-586.
[14] SHIN S J,CHUNG S,KIM S,et al.Effect of sodiumglucose co-transporter 2 inhibitor,dapagliflozin,on renal renin-angiotensin system in an animal model of type 2 diabetes[J].PLoS One,2016,11(1):e0165703.
[15] LIN B,KOIBUCHI N,HASEGAWA Y,et al.Glycemic control with empagliflozin,a novel selective SGLT2 inhibitor,ameliorates cardiovascular injury and cognitive dysfunction in obese andtype 2 diabetic mice[J].Cardiovasc Diabetol,2014,13:148.
[16] OJIMA A,MATSUI T,NISHINO Y,et al.An inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis[J].Horm Metab Res,2015,47(9):686-692.
[17] KOJIMA N,WILLIAMS J M,TAKAHASHI T,et al.Effects of a new SGLT2 inhibitor luseogliflozin,on diabetic nephropathy in T2DN rats[J].J Pharmacol Exp Ther,2013,345(3):464-472.
[18] TAHARA A,KUROSAKI E,YOKONO M,et al.Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia,oxidative stress,inflammation and liver injury in streptozotocin-induced type 1 diabetic rats[J].J Pharmacol Exp Ther,2014,66(7):975-987.
[19] SAKAI S,KAKU K,SEINO Y,et al.Efficacy and safety of the SGLT2 inhibitor luseogliflozin in japanese patients with type 2 diabetes mellitus stratified according to baseline body mass index:pooled analysis of data from 52-Week phase Ⅲ trials[J].Clin Ther,2016,38(4):843-862.
[20] CHERNEY D,LUND S S,PERKINS B A,et al.The effect of sodium glucose cotransporter 2 inhibitionwith empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes[J].Diabetologia,2016,59(9):1860-1870.
[21] OGAWA W,SAKAGUCHI K.Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors:possible mechanism and contributing factors[J].J Diabetes Invest,2016,7(2):135-138.
[22] TAKAKURA S,TOYOSHI T,HAYASHIZAKI Y,et al.Effect of ipragliflozin an SGLT2 inhibitor,on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats[J].Life Sci,2016,147:125-131.
[23] ABDUL-GHANI M A,NORTON L,DEFRONZO R A.Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus[J].Am J Physiol Renal Physiol,2015,309(11):889-900.
[24] LIN H W,TSENG C H.A review on the relationship between SGLT2 inhibitors and cancer[J].Int J Endocrinol,2014,doi:10.1155/2014/719578.
[25] SZALAT A,PERLMAN A,MUSZKAT M,et al.Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia[J].Drug Saf,2017,doi:10.1007/s40264-017-0602-6. |
